1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer. - Rimmel, B.; Bender, D.; Enserro, D.; Westin, S.; Powell, M.A.; Holman, L.; Moore, R.G.; Backes, F.; Musa, F.B.; DiSilvestro, P.; Godbee, N.; Gill, S.E.; et al. (Annals of Oncology, 2025)